Atlas of Genetics and Cytogenetics in Oncology and Haematology


Home   Genes   Leukemias   Solid Tumours   Cancer-Prone   Deep Insight   Case Reports   Journals  Portal   Teaching   

X Y 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 NA

Gallbladder: Carcinoma of the gallbladder and extrahepatic bile ducts

Written2007-06Munechika Enjoji, Toyoma Kaku
Department of Hepatology, Pancreatology, Kyushu University Hospital, 3-1-1 Maidashi, Higashi-ku, Fukuoka 812-8582, Japan

(Note : for Links provided by Atlas : click)

Identity

ICD-Topo C239-C241,C248-C249 GALLBLADDER & EXTRAHEPATIC BILE DUCTS
Atlas_Id 5275
Phylum Digestive organs:Gallbladder tumors and extrahepatic bile ducts (Biliary tract carcinoma, cholangiocarcinoma)
Other namesBiliary tract carcinoma, cholangiocarcinoma
Note Defined as a malignant epithelial tumor arising in the gall bladder and extrahepatic bile ducts including ampulla of Vater.
Extrahepatic bile duct carcinoma from the middle portion (percutaneous transhepatic cholangiography).

Classification

Note Tumor staging is separated by TNM classification (International Classification of Diseases, ICD).
    TNM classifications for carcinomas of the gallbladder, extrahepatic bile ducts and the ampulla of Vater.
The histopathological classification of biliary tract carcinoma follows WHO classification:
  • adenocarcinoma,
  • adenosquamous carcinoma,
  • squamous cell carcinoma,
  • small cell carcinoma,
  • adenoendocrine cell carcinoma,
  • undifferentiated carcinoma, and
  • carcinosarcoma.
  • Clinics and Pathology

    Disease Carcinoma of the gallbladder and extrahepatic bile ducts is an aggressive malignancy with a poor prognosis.
    Etiology Carcinoma of the gallbladder and extrahepatic bile ducts is more common in Eastern Europe and Latin American countries, and in the yellow races. It occurs frequently in older age groups (6th to 7th decades of life). Statistical data in Japan and USA indicate that gallbladder carcinomas occur predominantly in female, whereas carcinoma of the extrahepatic bile duct occurs more frequently in males. Carcinoma of the extrahepatic bile duct is associated with primary sclerosing cholangitis, ulcerative colitis, abnormal choledochopancreatic junction, and parasitic infection (trematode). In gallbladder carcinomas, gallstones and abnormal choledochopancreatic junction are considered risk factors. Association with smoking and drinking is not established.
    Epidemiology One of the common carcinomas worldwide
    Clinics The clinical symptoms are affected by the complications such as gallstones and cholangitis. The most frequent symptom is right upper quadrant pain in gallbladder carcinomas and obstructive jaundice in extrahepatic bile duct carcinomas. Chills and fever appear when cholangitis develops. For early diagnosis, ultrasonography is useful; detection of biliary dilatation and tumor masses. For staging, computed tomography, magnetic resonance imaging, and endoscopic ultrasonography are effective. Percutaneous transhepatic cholangiography and endoscopic retrograde cholangiography are poorly available for qualitative diagnosis but performed in case of biliary drainage.
    Cytology Cytology of bile duct brushings is an important diagnostic tool for tumors of biliary ductal system presenting as duct strictures from which it can be difficult to obtain a histology biopsy. Bile duct brushings have been recognized as a technique of moderate sensitivity and high specificity in identifying carcinoma. Reported diagnostic sensitivities for malignancy have ranged from 20 to 70% and specificity is almost 100%. Therefore, positive diagnoses of malignancy are of great clinical value but a negative result is relatively little clinical aid.
     
    Positive bile cytology specimen (Papanicolau stain). Isolated cells with increased nucleocytoplasmic ratio, marked anisocaryosis, loss of polarity, and prominent nucleoli.
     
    Carcinoma of the gallbladder; well differentiated adenocarcinoma.
    Treatment Surgical resection, chemotherapy, radiotherapy, immunotherapy
    Evolution Recurrence should be given care to.
    Prognosis The prognosis of biliary carcinomas depends primarily on the extent of disease. In inoperable cases, one-year survival rates in gallbladder carcinomas and extrahepatic bile duct carcinomas are 10% or less and 20% or less, respectively.

    Cytogenetics

    Note Loss of heterozygosity at chromosomal loci 8p, 9p, and 18q are frequently detected.

    Genes involved and Proteins

    Gene Name KRAS
    Location 12p12.1
    Dna / Rna 4 exons
    Protein Proto-oncogene. GTP-GDP binding protein with GTPase activity. The K-ras proto-oncogene is thought to exert control over some of the mechanisms of cell growth and differentiation. This gene is converted to an active oncogene by point mutations significantly concentrated in codons 12, 13, or 61. The incidence of the mutations has variously been reported to be 17-59% of gallbladder carcinomas and 23-100% of bile duct carcinomas. K-ras mutations in biliary tract carcinomas with a background of pancreaticobiliary maljunction is significantly higher than in those without it, namely, 50-100% and 6-36%, respectively. Alteration of the K-ras oncogene may be very important in the early stages of carcinogenesis of biliary mucosa, especially in association with anomalous connections of the pancreatobiliary ducts. K-ras mutation is more frequently detected in carcinomatous and dysplastic lesions in gallbladder carcinoma cases with gall stones than in those without stones. There was a large difference in the incidence of K-ras mutations between distal (47-75%) and middle or proximal (0-8%) bile duct carcinoma. The distal portion may be to some extent influenced by pancreatic juice because of its anatomical location. K-ras mutations in biliary tract carcinomas are not statistically significantly correlated with tumor staging, histological type and age, sex, or survival of the patients.

    Gene Name TP53
    Location 17p13
    Dna / Rna 11 exons
    Protein Tumor suppressor. Wild-type p53 plays an important role in the regulation of the cell cycle process, cell growth, and apoptosis in the event of DNA damage. The mutant proteins from the mutated genes disrupt critical growth-regulating mechanisms and may play a crucial role in the carcinogenesis. The reported incidence of p53 mutation is 31-92% in gallbladder carcinoma and 33-73% in bile duct carcinoma. In general, there is a tendency for higher grade carcinomas to express more p53 protein. p53 abnormalities may appear early during the transition from low-grade to higher-grade tumors and may play a role in the development of more malignant tumor phenotypes. A statistically significant difference is found for the incidence of p53 protein expression between extrahepatic bile duct carcinomas from the distal portion and those from the lower mid-region. This tendency is the same as that for K-ras mutations and the pancreaticobiliary maljunction may override the effect of p53 gene mutations.

    Gene Name CDKN2A
    Location 9p21
    Dna / Rna 3 exons
    Protein Regulatory protein in the cell cycle and cyclin-dependent kinase (cdk4/cdk6) inhibitor. The tumor suppressor gene p16 is commonly inactivated in many neoplasms. Three distinct mechanisms of p16 inactivation have been reported in biliary neoplasms: deletion and point mutations of the p16 gene, and hypermethylation of 5¹ regulatory regions of p16. It has been reported that 60-80% of primary biliary tract carcinomas had point mutations in the p16 gene. Allelic loss at the p16 locus on chromosome 9p21 or p16 promoter hypermethylation occurred with sufficient frequency in extrahepatic bile duct carcinomas and in gallbladder carcinomas. Therefore, the p16 gene may possibly be crucial for biliary tract carcinogenesis and progression.

    Gene Name ERBB2
    Location 17q21.1
    Dna / Rna 7 exons
    Protein Proto-oncogene. Amplification and overexpression of c-erbB-2 are frequently shown in biliary tract carcinomas. It is suggested that c-erbB-2 expression may be associated with neoplastic progression in biliary tracts.

    Bibliography

    K-ras gene mutation in gall bladder carcinomas and dysplasia.
    Ajiki T, Fujimori T, Onoyama H, Yamamoto M, Kitazawa S, Maeda S, Saitoh Y
    Gut. 1996 ; 38 (3) : 426-429.
    PMID 8675098
     
    Carcinoma of the gallbladder and extrahepatic bile ducts.
    AlboresSaavedra J, Menck HR, Scoazec JC, Soehendra N, Wittekind C, Sriram PVJ, Sripa B
    in..
     
    Inactivation of the INK4a/ARF locus and p53 in sporadic extrahepatic bile duct cancers and bile tract cancer cell lines.
    Caca K, Feisthammel J, Klee K, Tannapfel A, Witzigmann H, Wittekind C, Mössner J, Berr F
    International journal of cancer. Journal international du cancer. 2002 ; 97 (4) : 481-488.
    PMID 11802210
     
    Preliminary study of p53 and c-erbB-2 expression in gallbladder cancer in Indian patients manuscript id: 8962091628764582.
    Chaube A, Tewari M, Garbyal RS, Singh U, Shukla HS
    BMC cancer. 2006 ; 6 : page 126.
    PMID 16686942
     
    p53 protein immunoreactivity in extrahepatic bile duct and gallbladder cancer: correlation with tumor grade and survival.
    Diamantis I, Karamitopoulou E, Perentes E, Zimmermann A
    Hepatology (Baltimore, Md.). 1995 ; 22 (3) : 774-779.
    PMID 7657282
     
    K-ras and p53 mutations in stage I gallbladder carcinoma with an anomalous junction of the pancreaticobiliary duct.
    Hanada K, Itoh M, Fujii K, Tsuchida A, Ooishi H, Kajiyama G
    Cancer. 1996 ; 77 (3) : 452-458.
    PMID 8630951
     
    Gene mutations of K-ras in gallbladder mucosae and gallbladder carcinoma with an anomalous junction of the pancreaticobiliary duct.
    Hanada K, Tsuchida A, Iwao T, Eguchi N, Sasaki T, Morinaka K, Matsubara K, Kawasaki Y, Yamamoto S, Kajiyama G
    The American journal of gastroenterology. 1999 ; 94 (6) : 1638-1642.
    PMID 10364037
     
    K-ras codon 12 mutations in biliary tract tumors detected by polymerase chain reaction denaturing gradient gel electrophoresis.
    Imai M, Hoshi T, Ogawa K
    Cancer. 1994 ; 73 (11) : 2727-2733.
    PMID 8194013
     
    p16INK4 gene mutations are relatively frequent in ampullary carcinomas.
    Imai Y, Tsurutani N, Oda H, Nakatsuru Y, Inoue T, Ishikawa T
    Japanese journal of cancer research : Gann. 1997 ; 88 (10) : 941-946.
    PMID 9414654
     
    Correlation of p53 protein expression with gene mutation in gall-bladder carcinomas.
    Itoi T, Watanabe H, Yoshida M, Ajioka Y, Nishikura K, Saito T
    Pathology international. 1997 ; 47 (8) : 525-530.
    PMID 9293532
     
    General roles for surgical and pathological studies on cancer of the biliary tract.
    Japanese Society of Biliary Surgery
    In..
     
    p53 and c-erbB-2 protein expression in adenocarcinomas and epithelial dysplasias of the gall bladder.
    Kamel D, Pääkkö P, Nuorva K, Vähä K, Soini Y
    The Journal of pathology. 1993 ; 170 (1) : 67-72.
    PMID 8100854
     
    Multiple K-ras codon 12 mutations in cholangiocarcinomas demonstrated with a sensitive polymerase chain reaction technique.
    Levi S, Urbano-Ispizua A, Gill R, Thomas DM, Gilbertson J, Foster C, Marshall CJ
    Cancer research. 1991 ; 51 (13) : 3497-3502.
    PMID 1675933
     
    Relation between K-ras codon 12 mutation and p53 protein overexpression in gallbladder cancer and biliary ductal epithelia in patients with pancreaticobiliary maljunction.
    Masuhara S, Kasuya K, Aoki T, Yoshimatsu A, Tsuchida A, Koyanagi Y
    Journal of hepato-biliary-pancreatic surgery. 2000 ; 7 (2) : 198-205.
    PMID 10982614
     
    K-ras point mutations in cancerous and noncancerous biliary epithelium in patients with pancreaticobiliary maljunction.
    Matsubara T, Sakurai Y, Sasayama Y, Hori H, Ochiai M, Funabiki T, Matsumoto K, Hirono I
    Cancer. 1996 ; 77 (8 Suppl) : 1752-1757.
    PMID 8608574
     
    p53 expression as a prognostic determinant in resected distal bile duct carcinoma.
    Rijken AM, Offerhaus GJ, Polak MM, Gouma DJ, van Gulik TM
    European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology. 1999 ; 25 (3) : 297-301.
    PMID 10336811
     
    Diagnostic and prognostic value of incidence of K-ras codon 12 mutations in resected distal bile duct carcinoma.
    Rijken AM, van Gulik TM, Polak MM, Sturm PD, Gouma DJ, Offerhaus GJ
    Journal of surgical oncology. 1998 ; 68 (3) : 187-192.
    PMID 9701213
     
    Prognostic significance of Ki-67 and p53 antigen expression in carcinomas of bile duct and gallbladder.
    Shrestha ML, Miyake H, Kikutsuji T, Tashiro S
    The journal of medical investigation : JMI. 1998 ; 45 (1-4) : 95-102.
    PMID 9864969
     
    Assessment of the expression of p53, MIB-1 (Ki-67 antigen), and argyrophilic nucleolar organizer regions in carcinoma of the extrahepatic bile duct.
    Suto T, Sugai T, Nakamura S, Funato O, Nitta H, Sasaki R, Kanno S, Saito K
    Cancer. 1998 ; 82 (1) : 86-95.
    PMID 9428483
     
    Analysis of K-ras gene mutation in hyperplastic duct cells of the pancreas without pancreatic disease.
    Tada M, Ohashi M, Shiratori Y, Okudaira T, Komatsu Y, Kawabe T, Yoshida H, Machinami R, Kishi K, Omata M
    Gastroenterology. 1996 ; 110 (1) : 227-231.
    PMID 8536861
     
    Mutation of the p53 gene in gallbladder cancer.
    Takagi S, Naito E, Yamanouchi H, Ohtsuka H, Kominami R, Yamamoto M
    The Tohoku journal of experimental medicine. 1994 ; 172 (3) : 283-289.
    PMID 8073440
     
    An immunohistochemical study of p53 protein in gallbladder and extrahepatic bile duct/ampullary carcinomas.
    Teh M, Wee A, Raju GC
    Cancer. 1994 ; 74 (5) : 1542-1545.
    PMID 7520348
     
    Expression of p53 in adenocarcinoma of the gallbladder and bile ducts.
    Washington K, Gottfried MR
    Liver. 1996 ; 16 (2) : 99-104.
    PMID 8740842
     
    Point mutation of K-ras gene codon 12 in biliary tract tumors.
    Watanabe M, Asaka M, Tanaka J, Kurosawa M, Kasai M, Miyazaki T
    Gastroenterology. 1994 ; 107 (4) : 1147-1153.
    PMID 7926462
     
    Clinical importance of p53 protein in gall bladder carcinoma and its precursor lesions.
    Wee A, Teh M, Raju GC
    Journal of clinical pathology. 1994 ; 47 (5) : 453-456.
    PMID 8027399
     
    Allele-specific mutations involved in the pathogenesis of endemic gallbladder carcinoma in Chile.
    Wistuba II, Sugio K, Hung J, Kishimoto Y, Virmani AK, Roa I, Albores-Saavedra J, Gazdar AF
    Cancer research. 1995 ; 55 (12) : 2511-2515.
    PMID 7780959
     
    Mutations of p16Ink4/CDKN2 and p15Ink4B/MTS2 genes in biliary tract cancers.
    Yoshida S, Todoroki T, Ichikawa Y, Hanai S, Suzuki H, Hori M, Fukao K, Miwa M, Uchida K
    Cancer research. 1995 ; 55 (13) : 2756-2760.
    PMID 7796400
     

    Citation

    This paper should be referenced as such :
    Enjoji, M ; Kaku, T
    Digestive organs: Carcinoma of the gallbladder, extrahepatic bile ducts
    Atlas Genet Cytogenet Oncol Haematol. 2008;12(2):167-171.
    Free journal version : [ pdf ]   [ DOI ]
    On line version : http://AtlasGeneticsOncology.org/Tumors/GallbladderID5275.html


    Other genes implicated (Data extracted from papers in the Atlas) [ 33 ]

    Genes AGER AKT1 APAF1 APC BRCA2 CLIC1 CYP7A1 ERRFI1 GATA6 KCNH1
    MCM5 MKI67 MST1 MUC2 MUC5AC MUC5AC MUC6 NME1 NMT1
    EP300 PARK7 PLA2G4A PRKCI PTK2 RARRES3 RPRM RRM1 S100A4 SEMA3B
    SNCG STMN1 ZMYND10

    External links

    arrayMap Topo ( C23,C24) arrayMap ((UZH-SIB Zurich)   [auto + random 100 samples .. if exist ]   [tabulated segments]
     
     
    Other databaseCholangiocarcinoma (CHOL) TCGA Copy Number Portal
    Other databaseGallbladder Cancer Overview - Disease Synopsis [canSAR]
    Other databaseCholangiocarcinoma [ Genomic Data Commons - NCI TCGA-CHOL]
    Disease databaseGallbladder: Carcinoma of the gallbladder and extrahepatic bile ducts
    REVIEW articlesautomatic search in PubMed
    Last year articlesautomatic search in PubMed


    © Atlas of Genetics and Cytogenetics in Oncology and Haematology
    indexed on : Tue Mar 14 13:56:45 CET 2017


    Home   Genes   Leukemias   Solid Tumours   Cancer-Prone   Deep Insight   Case Reports   Journals  Portal   Teaching   

    For comments and suggestions or contributions, please contact us

    jlhuret@AtlasGeneticsOncology.org.